Annual CFF
N/A
December 1, 2024
Summary
- VKTX annual cash flow from financing activities is not available.
Performance
VKTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly CFF
N/A
December 1, 2024
Summary
- VKTX quarterly cash flow from financing activities is not available.
Performance
VKTX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFF
N/A
December 1, 2024
Summary
- VKTX TTM cash flow from financing activities is not available.
Performance
VKTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
VKTX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | - | - | - |
| 5 y5 years | - | - | - |
VKTX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time |
Viking Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $2.52 M(-13.2%) | $611.65 M(+0.4%) |
| Jun 2024 | - | $2.90 M(-99.5%) | $609.06 M(-30.3%) |
| Mar 2024 | - | $606.04 M(>+9900.0%) | $873.23 M(+221.8%) |
| Dec 2023 | $271.38 M(+6418.8%) | $188.00 K(-354.1%) | $271.38 M(-3.7%) |
| Sep 2023 | - | -$74.00 K(-100.0%) | $281.94 M(-0.0%) |
| Jun 2023 | - | $267.08 M(+6283.3%) | $282.02 M(+2012.0%) |
| Mar 2023 | - | $4.18 M(-61.1%) | $13.35 M(+220.8%) |
| Dec 2022 | $4.16 M(-39.5%) | $10.75 M(>+9900.0%) | $4.16 M(-163.7%) |
| Sep 2022 | - | $10.00 K(-100.6%) | -$6.54 M(-3.9%) |
| Jun 2022 | - | -$1.59 M(-68.2%) | -$6.80 M(+105.2%) |
| Mar 2022 | - | -$5.01 M(<-9900.0%) | -$3.32 M(-148.2%) |
| Dec 2021 | $6.88 M(+624.2%) | $47.00 K(-118.4%) | $6.88 M(-5.7%) |
| Sep 2021 | - | -$256.00 K(-113.5%) | $7.30 M(-3.9%) |
| Jun 2021 | - | $1.90 M(-63.4%) | $7.59 M(+24.3%) |
| Mar 2021 | - | $5.19 M(+1018.8%) | $6.11 M(+542.9%) |
| Dec 2020 | $950.00 K(+7.1%) | $464.00 K(+1154.1%) | $950.00 K(+32.9%) |
| Sep 2020 | - | $37.00 K(-91.1%) | $715.00 K(-4.8%) |
| Jun 2020 | - | $416.00 K(+1160.6%) | $751.00 K(+26.2%) |
| Mar 2020 | - | $33.00 K(-85.6%) | $595.00 K(-32.9%) |
| Dec 2019 | $887.00 K(-99.7%) | $229.00 K(+213.7%) | $887.00 K(-11.4%) |
| Sep 2019 | - | $73.00 K(-71.9%) | $1.00 M(-99.4%) |
| Jun 2019 | - | $260.00 K(-20.0%) | $168.41 M(-29.3%) |
| Mar 2019 | - | $325.00 K(-5.2%) | $238.30 M(-20.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | $300.27 M(+1240.5%) | $343.00 K(-99.8%) | $300.27 M(-4.6%) |
| Sep 2018 | - | $167.49 M(+138.8%) | $314.69 M(+112.2%) |
| Jun 2018 | - | $70.15 M(+12.6%) | $148.32 M(+80.5%) |
| Mar 2018 | - | $62.30 M(+322.0%) | $82.17 M(+266.8%) |
| Dec 2017 | $22.40 M(+116.5%) | $14.76 M(+1228.8%) | $22.40 M(+158.2%) |
| Sep 2017 | - | $1.11 M(-72.2%) | $8.68 M(+13.1%) |
| Jun 2017 | - | $4.00 M(+58.6%) | $7.67 M(-40.7%) |
| Mar 2017 | - | $2.52 M(+143.1%) | $12.93 M(+24.9%) |
| Dec 2016 | $10.35 M(-53.4%) | $1.04 M(+858.7%) | $10.35 M(+11.5%) |
| Sep 2016 | - | $108.30 K(-98.8%) | $9.28 M(+9.6%) |
| Jun 2016 | - | $9.26 M(<-9900.0%) | $8.47 M(-61.8%) |
| Mar 2016 | - | -$57.30 K(+103.2%) | $22.17 M(-0.2%) |
| Dec 2015 | $22.21 M(+924.8%) | -$28.20 K(-96.0%) | $22.21 M(-1.9%) |
| Sep 2015 | - | -$704.70 K(-103.1%) | $22.64 M(-5.1%) |
| Jun 2015 | - | $22.96 M(<-9900.0%) | $23.86 M(+1010.0%) |
| Mar 2015 | - | -$17.90 K(-104.4%) | $2.15 M(-0.8%) |
| Dec 2014 | $2.17 M(+740.5%) | $402.40 K(-21.5%) | $2.17 M(+22.8%) |
| Sep 2014 | - | $512.80 K(-59.1%) | $1.77 M(+40.9%) |
| Jun 2014 | - | $1.25 M(>+9900.0%) | $1.25 M(+481.5%) |
| Mar 2014 | - | $0.00(-100.0%) | $215.40 K(0.0%) |
| Dec 2013 | $257.90 K | - | - |
| Jun 2013 | - | $215.40 K(>+9900.0%) | $215.40 K(>+9900.0%) |
| Mar 2013 | - | $0.00 | $0.00 |
FAQ
- What is the all time high annual CFF for Viking Therapeutics?
- What is the all time high quarterly CFF for Viking Therapeutics?
- What is the all time high TTM CFF for Viking Therapeutics?
What is the all time high annual CFF for Viking Therapeutics?
Viking Therapeutics all-time high annual cash flow from financing activities is $300.27 M
What is the all time high quarterly CFF for Viking Therapeutics?
Viking Therapeutics all-time high quarterly cash flow from financing activities is $606.04 M
What is the all time high TTM CFF for Viking Therapeutics?
Viking Therapeutics all-time high TTM cash flow from financing activities is $873.23 M